MTOR and cancer: In addition to the classical gene set enrichment, the variants are checked against five cancer-associated signaling pathways, namely PI3K-AKT-mTOR, RAF-MEK-ERK, DNA Damage Response, Cell Cycle and Tyrosine Kinases, that play a role in known cancer processes.